ArticlePloS one2026
Structural transformation of a hydrogel-forming cell division protein ZapB of multidrug resistant Klebsiella pneumoniae with small molecules.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Septal ring assembly protein ZapB (EMR18431.1) is involved in Z-ring formation, and nucleoid segregation during the bacterial cell division . It promotes cell division in the initial stages of the cell cycle through direct interaction with FtsZ, thus stimulating Z-ring assembly. The ZapB inhibition can make bacterial cell susceptible to primary antibiotics, and therefore considered as an important approach for adjuvent therapy against MDR bacterial infections. Hence in the current study, ZapB protein of multidrug resistant Klebsiella pneumoniae was cloned, and expressed in E. coli system. To understand its role, and to assess the mechanism of ZapB activation, the characteristic microstructure of ZapB filament network were analyzed by scanning electron microscopy (SEM). ZapB self assembles into long filaments in a concentration dependent manner, and arranges themselves in meshworks, leading to polymeric forms. Furthermore, the effects of 26 compounds, including US-FDA approved drugs, and synthetic compounds of various chemical classes, on the filament formation ability of ZapB were studied by using SEM, and in silico methods. Among them, 5 compounds were found to disrupt the microstructure of ZapB, including trimethoprim (1), amikacin sulphate (2), hydroquinone (3), tobramycin (4), and bis(4-hydroxyphenyl) sulfide (5). Quantitative analysis demonstrated that morphological parameters of ZapB filament were significantly reduced following - treatment with test compounds. Among them, compound 2 showed the most pronounced effect, reducing filament length to 35.48 ± 21.55 µm (mean ± SD), whereas untreated ZapB filaments have an average length of 205.38 ± 89.34 µm, and broadest average diameter of 23.67 ± 7.71 µm. Molecular docking studies further predicted their non-covalent interactions with ZapB protein via hydrogen bond, salt bridges, and aromatic hydrogen bonds. Better understanding of the hydrogelation mechanism of ZapB, and its disruption is important for the development of new inhibitors of the cell division of bacteria. This can, therefore, serve as an important approach for the multi-target treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.